While acquisition of novel mutations may be one of the possible explanations to this resistance in clinical treatment, activating mutations of several RTKs including ErbB2, ErbB3 and c-MET were discovered in human colorectal cancer and other cancers [23]–[27]. This evidence concerns the gene ERBB3 and cancer.